Autoimmune Diseases Treatment Market in China 2021

USD 450

Product Type

Industry Statistics

Release Date

15 March 2021

Region

Asia Pacific

Release Year

2021

Table of Contents
    Add a header to begin generating the table of contents

    Description

    The autoimmune diseases treatment market in China in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 27% during the forecast period, according to data and analytics company StrategyHelix.

    The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for autoimmune diseases treatment. The China autoimmune diseases treatment market is segmented on the basis of product, type. By product, it is categorized into biologics, and small molecule chemical drugs. The small molecule chemical drugs segment held the largest market share in 2020. However, the biologics segment is expected to witness the highest CAGR during the forecast period. By type, the autoimmune diseases treatment market is divided into immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE).

    The report has profiled some of the key players of the market such as UCB S.A., AbbVie Inc., GlaxoSmithKline plc., Janssen Pharmaceutica NV, Novartis International AG, Pfizer Inc., Roche Holding AG, Rongchang Pharmacy Co. Ltd..

    The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the autoimmune diseases treatment market to help drive informed decision making for industry executives, policy makers, academic, and analysts.


    Report Scope

    Product: biologics, and small molecule chemical drugs
    Type: immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE)
    Years Considered: this report covers the period 2017 to 2027


    Key Benefits for Stakeholders

    Get a comprehensive picture of the China autoimmune diseases treatment market
    Pinpoint growth sectors and trends for investment
    Understand what the future of the autoimmune diseases treatment market in China looks like
    Identify the competitive landscape and window of opportunity


    Table of Contents

    1. Market Definition
    2. Research Methodology
    3. Market Data & Outlook
    3.1 Market Value
    3.2 Market Value Forecast
    4. Autoimmune Diseases Treatment Market by Product
    4.1 Biologics
    4.2 Small Molecule Chemical Drugs
    5. Autoimmune Diseases Treatment Market by Type
    5.1 Immunoglobulin A Nephropathy (IgAN)
    5.2 Multiple Sclerosis (MS)
    5.3 Myasthenia Gravis (MG)
    5.4 Neuromyelitis Optica Spectrum Disorder (NMOSD)
    5.5 Rheumatoid Arthritis (RA)
    5.6 Sjogren’S Syndrome (SS)
    5.7 Systemic Lupus Erythematosus (SLE)
    6. Company Profiles
    6.1 UCB S.A.
    6.2 AbbVie Inc.
    6.3 GlaxoSmithKline plc.
    6.4 Janssen Pharmaceutica NV
    6.5 Novartis International AG
    6.6 Pfizer, Inc.
    6.7 Roche Holding AG
    6.8 Rongchang Pharmacy Co., Ltd.
    7. Appendix
    7.1 About StrategyHelix
    7.2 Disclaimer


    StrategyHelix Black LOGO

    REQUEST SAMPLE

    Please fill out our form and we will get back to you.

    Autoimmune Diseases Treatment Market in China 2021

    StrategyHelix Black LOGO

    CUSTOM RESEARCH

    Custom projects can be researched to match your unique needs.

    Autoimmune Diseases Treatment Market in China 2021

    login